Q1 Operating Loss of 44.5 Billion Won, Widening Loss YoY
-
Revenue 168.6 billion won, up 9.1% YoY, down 8.5% QoQ
-
Operating loss 44.5 billion won, worsening from -15.1 billion won YoY
-
Net loss 36.2 billion won, significantly widened from -4.1 billion won YoY
-
Controlling interest net loss 33.3 billion won, improved 42.5% QoQ but deteriorated YoY
-
Preliminary results subject to change after auditor review
KOSPI Filing Information
-
Filing: Consolidated Financial Statements Basis Operating (Provisional) Results (Fair Disclosure)
-
Company: SK Bioscience (302440)
-
Submission: SK Bioscience Co.,Ltd
-
Receipt: 05-06-2026
-
Under KRX KOSPI Market Division